Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD99 molecule-like 2 (CD99L2)
- Target
- CD99L2
- Molecular classification
- Cell adhesion molecule, Type I membrane glycoprotein, Immunoglobulin superfamily (by sequence and function resemblance, though not always formally classified)
01
Overview
CD99 molecule-like 2 (CD99L2) is a type I transmembrane glycoprotein expressed on both vascular endothelial cells and leukocytes[1][3][4]. It is critically involved in controlling the process of leukocyte extravasation during inflammation by facilitating the diapedesis of neutrophils and monocytes across the endothelial barrier. CD99L2 functions as a homophilic cell adhesion molecule at endothelial junctions and regulates a unique step in leukocyte transendothelial migration, operating between the action of PECAM-1 (CD31) and CD99. Inhibition or knockout of CD99L2 impairs leukocyte recruitment to inflamed tissues, highlighting its central role in immune cell trafficking during inflammation[1][4]. Its modulation is a potential therapeutic strategy for regulating inflammatory responses, though no approved drugs currently target CD99L2 directly.
- Other names
- CD99 antigen-like protein 2MIC2L1CD99BMIC2-like protein 1UNQ1964/PRO4486
02
Mechanism of action
Antibody blockade impairs leukocyte transmigration by preventing homophilic adhesion at the endothelial barrier[1][4]
03
Biological functions
Leukocyte extravasationCell adhesionRegulation of inflammatory cell traffickingImmune response modulation
04
Disease associations
InflammationPotential involvement in cancer (e.g., differential expression linked to tumor datasets and some rare tumor types[3])
05
Safety considerations
Therapeutic targeting may impair normal inflammatory response and immune cell trafficking, increasing infection risk or altering inflammation[1][4]
06
Biomarkers
Expression in tissue and tumors (as measured in TCGA and proteomic datasets), especially in relation to inflammation and possibly tumor biology[1]
Beyond the preview
Go deeper on CD99 molecule-like 2 (CD99L2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD99 molecule-like 2 (CD99L2).